Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLOPI-SNAP: Clopidogrel as Adjuvant Drug in Staphylococcus Aureus Bacteraemia
NCT07384702Phase 2Not yet recruiting
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Jun 2026
- Primary completion
- Jun 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of clopidogrel in Staphylococcus aureus bacteremia (SAB) (2 arms), sponsored by Fundación Pública Andaluza para la Gestión de la Investigación. Primary endpoint: Desirability of Outcome Ranking at 90 days. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
clopidogrel
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT07384702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07384702.